Gastrointestinal and Hepatic Manifestations of Chronic Granulomatous Disease.

J Allergy Clin Immunol Pract

Translational Hepatology Section, Liver Diseases Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Md. Electronic address:

Published: May 2023

Chronic granulomatous disease (CGD) is a rare inborn error of immunity, resulting from a defect in nicotinamide adenine dinucleotide phosphate oxidation and decreased production of phagocyte reactive oxygen species. The main clinical manifestations are recurrent infections and chronic inflammatory disorders. Current approaches to management include antimicrobial prophylaxis and control of inflammatory complications. Hematopoietic stem cell transplantation or gene therapy can provide definitive treatment. Gastrointestinal and hepatic manifestations are common in CGD and include structural changes, dysmotility, CGD-associated inflammatory bowel disease, liver abscesses, and noncirrhotic portal hypertension. The findings can be heterogeneous, and the management is complex in light of the underlying immune dysfunction. This review describes the various clinical findings and the latest studies in management of gastrointestinal and hepatic manifestations in CGD, as well as the management experience at the National Institutes of Health.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2022.12.039DOI Listing

Publication Analysis

Top Keywords

gastrointestinal hepatic
12
hepatic manifestations
12
chronic granulomatous
8
granulomatous disease
8
manifestations
4
manifestations chronic
4
disease chronic
4
disease cgd
4
cgd rare
4
rare inborn
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!